Predicting Weight Loss in People With Cancer: Development of a Screening Tool
18 Years
N/A
Both
Cachexia, Gastrointestinal Cancer, Hematopoietic/Lymphoid Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Trial Information
Predicting Weight Loss in People With Cancer: Development of a Screening Tool
OBJECTIVES:
- To identify people with cancer who are at greatest risk of future weight loss by the
development of a simple and practical screening tool.
- To estimate the reliability of the Appetite and Symptom Questionnaire (part 1).
- To develop a screening tool based on the ability of the optimal combination of items
from the three measures (ASQ, MUST, CRP) to predict clinically significant weight loss
over three months (part 2).
- To estimate the sensitivity and specificity at various cut-points of the developed
screening tool in predicting clinically significant weight loss (> 10% weight loss or
between 5% and 10% weight loss with a BMI < 20 kg/m^2) over three months (part 2).
OUTLINE: This is a two-part study.
- Part 1: Patients are asked to complete the Appetite and Symptom Questionnaire (ASQ) on
two occasions, one week apart.
- Part 2: Patients are screened at baseline for risk of malnutrition using the
Malnutrition Universal Screening Tool. Blood samples are also taken at this time to
establish the level of C-reactive protein and patients complete the ASQ. Patients are
weighed using calibrated scales and height measurements are obtained. Patients are
asked about unplanned weight loss over the previous 3-6 months. Patients are weighed
again at 3 months. Percentage weight loss is calculated at 3 months.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Meets 1 of the following criteria, depending on part of study:
- Part 1:
- Receiving radiotherapy for cancer at Nottingham City Hospital
- Likely to be clinically stable over the duration of one week (i.e., not at
high risk of disease or treatment-related appetite and weight loss)
- Stable weight and appetite
- Part 2:
- Outpatient at Nottingham City Hospital with a confirmed diagnosis of
primary lung or gastrointestinal cancer
- Lost no more than 10% of pre-illness stable body weight
- Lost no more than 5% of pre-illness stable body weight if body mass index
(BMI) was less than 20 kg/m^2
- BMI ≥ 18.5 kg/m^2
PATIENT CHARACTERISTICS:
- No condition impairing the ability to swallow
- Not receiving enteral tube feeding or parenteral nutrition (part 2)
- Able to be weighed (part 2)
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent radiotherapy to the head, neck or upper gastrointestinal tract area
Type of Study:
Interventional
Study Design:
Primary Purpose: Supportive Care
Outcome Measure:
Percentage weight loss by measuring height and weight at baseline and at 3 months
Safety Issue:
No
Principal Investigator
Vanessa Halliday, MSC
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Nottingham
Authority:
United States: Federal Government
Study ID:
CDR0000590278
NCT ID:
NCT00710632
Start Date:
September 2007
Completion Date:
Related Keywords:
- Cachexia
- Gastrointestinal Cancer
- Hematopoietic/Lymphoid Cancer
- Lung Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
- cachexia
- lung cancer
- gastrointestinal cancer
- unspecified adult solid tumor, protocol specific
- hematopoietic/lymphoid cancer
- Cachexia
- Lung Neoplasms
- Weight Loss
- Gastrointestinal Neoplasms
Name | Location |
|---|
